MedTrace Logo

FPT155 in Patients With Advanced Solid Tumors

NCT04074759 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-01-23

Study results available
· View outcomes & findings →

Summary

This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of FPT155 as monotherapy in patients with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

FPT155

A soluble CD80 fusion protein

BIOLOGICAL

pembrolizumab

An anti-PD1 antibody

Sponsors & Collaborators

  • Five Prime Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-18
Primary Completion
2021-08-10
Completion
2021-08-10

Countries

  • Australia
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04074759 on ClinicalTrials.gov